Literature DB >> 872609

Pharmacology of Bay g 2821, a long-acting, high-ceiling diuretic.

K Meng, D Loew, K Stoepel, F Hoffmeister.   

Abstract

Bay g 2821 is a diuretic, from a new class of chemical substances, with both the efficacy of diuretics with a high-ceiling activity, such as furosemide, bumetanide and ethacrynic acid, and the prolonged duration of action of thiazides. Pharmacological investigations showed that Bay g 2821 was more potent than furosemide in dogs but less potent in rats. Bay g 2821 did not differ from furosemide in excretion of electrolytes. Further studies showed that Bay g 2821 had an antihypertensive effect in dogs, spontaneously hpertensive rats, and in rats with artificially-induced renal hypertension. Other pharmacological studies did not reveal any other significant effects.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 872609     DOI: 10.1185/03007997709115270

Source DB:  PubMed          Journal:  Curr Med Res Opin        ISSN: 0300-7995            Impact factor:   2.580


  9 in total

1.  Inhibition of ion transport in Ehrlich cells by muzolimine.

Authors:  P Geck; B Pfeiffer
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1986-07       Impact factor: 3.000

2.  Comparison of the pharmacodynamic effect of muzolimine and furosemide in patients with advanced chronic renal insufficiency.

Authors:  P Schmidt; D Loew; J Dýcka; H Kopsa; P Balcke; J Zazgornik; E Deutsch
Journal:  Eur J Clin Pharmacol       Date:  1978-12-18       Impact factor: 2.953

3.  Comparison of the pharmacodynamic effects of furosemide and BAY g 2821 and correlation of the pharmacodynamics and pharmacokinetics of BAY g 2821 (muzolimine).

Authors:  D Loew; W Ritter; J Dycka
Journal:  Eur J Clin Pharmacol       Date:  1977-12-16       Impact factor: 2.953

Review 4.  Clinical pharmacokinetics of some newer diuretics.

Authors:  B Beermann; M Grind
Journal:  Clin Pharmacokinet       Date:  1987-10       Impact factor: 6.447

5.  Comparison between the cardiac effects induced by muzolimine and furosemide in guinea-pig atria.

Authors:  P Dorigo; R M Gaion; M Bergamin; A Giacometti; E Valentini; I Maragno
Journal:  Cardiovasc Drugs Ther       Date:  1990-12       Impact factor: 3.727

6.  Bioavailability and elimination kinetics of the combination furosemide-retard/triamterene.

Authors:  O Schuster; D Loew; H E Knoell
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1985 Apr-Jun       Impact factor: 2.441

7.  Cross-over study of muzolimine and hydrochlorothiazide-amiloride in hypertensive patients.

Authors:  L A Ferrara; P Strazzullo; A Scillitani; M Mancini; R Gagliardi
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

8.  Metabolic effects of long-term therapy with muzolimine and chlorthalidone in hypertension.

Authors:  F Galletti; P Strazzullo; R Gagliardi; M Cirillo; A Siani; R Iacone; M Mancini
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

9.  Antihypertensive mechanism of the diuretic muzolimine in mild renal failure. Roles of sodium and cardiovascular norepinephrine responsiveness.

Authors:  H Schiffl; P Weidmann; C Beretta-Piccoli; C Cottier; A J Seiler; W H Ziegler
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.